From 1The Jean Hailes Foundation, Clayton, Australia, and the Department of Medicine, CECS, Monash University, Prahran, Victoria, Australia; 2Department of Obstetrics and Gynaecology, VU University Medical Centre, Amsterdam, The Netherlands; 3Department of Sexology & Psychosomatic Obstetrics/Gynaecology, Academic Medical Centre, University of Amsterdam, The Netherlands; 4Hopital Mere et Enfants, Service de Gynecologie Obstetrique, Nantes Cedex, France; 5Endocrinology Department, CHU Rangueil, Toulouse, France; 6John Radcliffe Hospital, Women's Centre, Headington, Oxford, UK; 7Procter & Gamble Pharmaceuticals, Egham, Surrey, UK; 8Procter & Gamble Pharmaceuticals, Health Care Research Center, Mason, OH; and 9Edinburgh Osteoporosis Centre, Edinburgh, Scotland.
Receive May 6, 2005; revised and accepted July 12, 2005.
This study was funded by Procter & Gamble Pharmaceuticals.
Address correspondence to: Susan R. Davis, MD, PhD, Department of Medicine, Monash University, Alfred Hospital, Prahran, Victoria, 3181, Australia. E-mail: [email protected].